Ultra-small prussian blue nano-particles carrying tirofian, preparation method and application of nano-particles in preparation of medicine for reducing MVO and MIRI

By preparing ultra-small Prussian blue nanoparticles carrying tirofiban, the risks of systemic bleeding and therapeutic limitations of existing drugs in treating microvascular obstruction and myocardial ischemia-reperfusion injury in patients with myocardial infarction were addressed. This approach achieved highly efficient scavenging of reactive oxygen species and antioxidant and anti-inflammatory effects at the coronary thrombus site, reducing the adverse effects of systemic exposure.

CN121622927APending Publication Date: 2026-03-10ZHUJIANG HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY
0 Cites 2 Cited by

Patent Information

Application Number
CN202511916651.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-12-18
Publication Date
2026-03-10

AI Technical Summary

Technical Problem

While existing drugs for treating microvascular obstruction and myocardial ischemia-reperfusion injury in patients with myocardial infarction, such as tirofiban, are effective, they carry the risk of systemic bleeding and cannot simultaneously resolve the vicious cycle of microvascular obstruction, oxidative stress, and inflammation.

Method used

Ultra-small Prussian blue nanoparticles carrying tirofiban were prepared by synthesizing nanoparticles with potassium ferricyanide, polyvinylpyrrolidone, and hydrochloric acid-ethanol solution, and then coupled with CREKA peptide to form nanoparticles with catalase and superoxide dismutase mimicking nanozyme activities, which can target thrombus sites and reduce systemic exposure.

Benefits of technology

It achieves efficient removal of reactive oxygen species at the site of coronary thrombosis, reduces systemic adverse effects, rapidly improves microvascular perfusion, and continuously exerts antioxidant and anti-inflammatory effects, effectively preventing microvascular damage and MIRI.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to ultra-small prussian blue nano-particles (T-USPB-C) carrying tirofian, a preparation method of the nano-particles and application of the nano-particles in preparation of drugs for reducing MVO and MIRI. According to the preparation method, the T-USPB-C is prepared by three steps. The T-USPB-C provided by the invention can carry tirofiban, and has catalase and superoxide dismutase simulated nano-enzyme activity. Moreover, the size of the nano-scale drug is required to reach a nano-scale size, and the drug can be efficiently cleared through kidney excretion, so that the potential long-term toxicity problem is minimized. The ultra-small prussian blue nanoparticle carrying the tirofian has an excellent active oxygen scavenging capability. Microvascular perfusion can be rapidly improved through the antithrombotic effect, then the protection effect is continuously achieved through the anti-oxidation and anti-inflammatory mechanism, and microvascular injury and MIRI are effectively prevented.
Need to check novelty before this filing date? Find Prior Art